Alkem Laboratories launches Olesoft Trucera, an advanced ceramide-boosting moisturizing lotion
The new product launch enhances Alkem's offering in an existing strong segment (moisturizers) and targets a high-growth area (dermatology), leveraging its established market position and potentially contributing to revenue growth.
The launch of a new, advanced product expands Alkem's portfolio in the growing dermatology segment and aligns with its strategic focus on high-growth therapy areas, indicating positive business development.
Alkem Laboratories Limited announced on August 19, 2025, the launch of Olesoft Trucera moisturizing lotion. * The product is an advanced science-led formulation designed to restore hydration, strengthen the skin barrier, and soothe skin flare-ups. * Olesoft Trucera contains N-Palmitoyl Serinol to stimulate natural ceramide production, a blend of five ceramides for moisture lock-in, and dual oat-extract actives with Niacinamide for anti-inflammatory benefits. * The lotion will be available on prescription. * Dr. Vikas Gupta, CEO of Alkem, stated that the launch strengthens Alkem's presence in advanced skincare with evidence-backed solutions, reflecting a strategy to focus on smart product selection in high-growth therapy areas. * Alkem already has a strong presence in the moisturizer segment with its Olesoft range, including Olesoft Max, which was the most prescribed moisturizer by dermatologists in India as of April 2025, and Olesoft Lite, named “Best Launch of the Year” in June 2025.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.